February 2nd, 2009 - 03:49 GMT Aclasta® Approved in Jordan as the first once-yearly treatment for women with postmenopausal osteoporosis Aclasta® (zoledronic acid 5 mg) has received the Jordan Food and Drug Administration (JFDA) approval as the first once-yearly bisphosphonate treatment Read more
